# Pardeep S. Jhund

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pardeep-s-jhund/

## Facts

| Field | Value |
| --- | --- |
| Citations | 45,947 |
| Field | Heart Failure Treatment and Management |
| h-index | 100 |
| i10-index | 391 |
| Last Known Institution | Brigham and Women's Hospital |
| OpenAlex ID | https://openalex.org/A5018432247 |
| ORCID iD | 0000-0003-4306-5317 |
| Works | 732 |

## Researcher papers

Showing 12 of 25.

- [Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-patients-with-heart-failure-and-reduced-ejection-fraction/)
- [Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/dapagliflozin-in-heart-failure-with-mildly-reduced-or-preserved-ejection/)
- [Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/angiotensin-neprilysin-inhibition-in-heart-failure-with-preserved-ejection/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in/)
- [SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials](https://scholariq.org/papers/sglt2-inhibitors-in-patients-with-heart-failure-a-comprehensive-meta-analysis-of/)
- [Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/)
- [Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials](https://scholariq.org/papers/estimating-lifetime-benefits-of-comprehensive-disease-modifying-pharmacological/)
- [Heart Failure and Chronic Obstructive Pulmonary Disease: Diagnostic Pitfalls and Epidemiology](https://scholariq.org/papers/heart-failure-and-chronic-obstructive-pulmonary-disease-diagnostic-pitfalls-and/)
- [Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes](https://scholariq.org/papers/effect-of-dapagliflozin-on-worsening-heart-failure-and-cardiovascular-death-in/)
- [Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003](https://scholariq.org/papers/long-term-trends-in-first-hospitalization-for-heart-failure-and-subsequent/)
- [Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure](https://scholariq.org/papers/renal-effects-and-associated-outcomes-during-angiotensin-neprilysin-inhibition/)
- [Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)](https://scholariq.org/papers/effect-of-empagliflozin-on-left-ventricular-volumes-in-patients-with-type-2/)

## Researcher topics

- [Heart Failure Treatment and Management](https://scholariq.org/topics/heart-failure-treatment-and-management/)
- [Cardiovascular Function and Risk Factors](https://scholariq.org/topics/cardiovascular-function-and-risk-factors/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Hyperglycemia and glycemic control in critically ill and hospitalized patients](https://scholariq.org/topics/hyperglycemia-and-glycemic-control-in-critically-ill-and-hospitalized-patients/)

## Researcher university

- [Brigham and Women's Hospital](https://scholariq.org/institutions/brigham-and-women-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.